Curative Biosciences

Curative Biosciences EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curative Biosciences (CBDX) as of Nov 3, 2026 is -53,200.00 USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.64 M USD — a change of -96.76% (higher).

EBITDA

-53,200.00USD

YoY

-96.76%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curative Biosciences is 2017 -53,200.00 USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curative Biosciences was 2016 -1.64 M USD. It decreases by -96.76% higher compared to the previous year.

The Curative Biosciences EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2014
-468,658.00 USD
Jan 1, 2015
-1.71 M USD
Jan 1, 2016
-1.64 M USD
Jan 1, 2017
-53,200.00 USD
The Curative Biosciences EBITDA history
YEAREBITDAYoY
-53,200.00USD-96.76%
-1.64 MUSD-3.78%
-1.71 MUSD+263.94%
-468,658.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curative Biosciences Stock analysis

What does Curative Biosciences do? Curative Biosciences Inc is a biotechnology company specializing in the development of innovative therapies for serious diseases. The company was founded in 2011 by a group of experienced scientists, medical experts, and entrepreneurs and is based in San Francisco, California. History Curative Biosciences Inc aims to develop groundbreaking therapies for diseases that currently have no effective treatment options. The company has had an impressive track record in recent years, as evidenced by numerous awards and recognition from reputable institutions and media. Business Model Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. The company conducts intensive research to identify and develop promising drug candidates. Divisions Curative Biosciences Inc has focused on several divisions to offer a wide range of innovative therapy options: - Oncology: Curative Biosciences Inc has developed a portfolio of drug candidates that specifically target malignant tumors without damaging healthy tissue. - Autoimmune diseases: The company has also developed some promising drug candidates for autoimmune diseases that regulate the immune system and reduce the risk of side effects and complications. - Neurodegenerative diseases: Curative Biosciences Inc is intensively working on the development of therapies against neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Products The company has already developed several promising products that are currently in clinical trials. Here are some examples: - CB-01: A drug candidate specifically developed to target aggressive tumors such as lung cancer, pancreatic cancer, and leukemia. - CB-02: A drug candidate that regulates the immune system and could be used in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. - CB-03: A promising drug candidate against Alzheimer's disease that reduces β-amyloid proteins in the brain and could slow down the progression of the disease. Summary Curative Biosciences Inc is an emerging biotechnology company specializing in the development of innovative therapies for serious diseases. The company conducts intensive research and has already developed several promising drug candidates that are currently in clinical trials. Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. Curative Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curative Biosciences stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curative Biosciences is -53,200.00 USD in 2017.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curative Biosciences changed from -1.64 M USD to -53,200.00 USD, representing a -96.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Curative Biosciences since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Curative Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Curative Biosciences

All Key Metrics — Curative Biosciences